Author

James L Gulley

National Cancer Institute - Cited by 26,575 - Immunotherapy - Prostate cancer

Biography

Dr James L Gulley is an internationally recognized expert in cancer immunotherapy with a strong interest in prostate cancer. Since 1998 he has authored and run a variety of clinical trials at the NCI. These innovative, investigator-initiated studies involve the use of cancer immunotherapy to (a) initiate immune responses, (b) expand immune responses and/or (c) allow the immune responses to be effective within the tumour microenvironment.
Title
Cited by
Year
Enhanced neoepitope-specific immunity following neoadjuvant PD-L1 and TGF-β blockade in HPV-unrelated head and neck cancer
JM Redman, J Friedman, Y Robbins, C Sievers, X Yang, W Lassoued, ...The Journal of clinical investigation 132 (18), 2022202
11
2022
A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1)
M Bilusic, NJ Toney, RN Donahue, S Wroblewski, M Zibelman, P Ghatalia, ...Prostate Cancer and Prostatic Diseases 25 (4), 735-740, 2022202
9
2022
Predicting Outcomes of Indeterminate Bone Lesions on 18F-DCFPyL PSMA PET/CT Scans in the Setting of High-Risk Primary or Recurrent Prostate Cancer
TE Phelps, SA Harmon, E Mena, L Lindenberg, JH Shih, DE Citrin, ...Journal of Nuclear Medicine 64 (), 95-401, 20220
3
2023
Bintrafusp Alfa: A Bifunctional Fusion Protein Targeting PD-L1 and TGF-β, in Patients with Pretreated Colorectal Cancer: Results from a Phase I Trial
A Spira, MS Wertheim, EJ Kim, B Tan, HJ Lenz, P Nikolinakos, PL Rich, ...The oncologist 28 (2), e124-e127, 20220
3
2023
Characteristics of patients admitted to the ICU with Kaposi sarcoma herpesvirus-associated diseases
ME Hansen, R Mangusan, K Lurain, T Odeny, J George, C Lu, M Manion, ...AIDS 6 (14), 1969-1978, 2022202
3
2022
Preclinical and clinical studies of bintrafusp alfa, a novel bifunctional anti-PD-L1/TGFβRII agent: Current status
SR Gameiro, J Strauss, JL Gulley, J SchlomExperimental Biology and Medicine 247 (1), 1124-114, 2022202
3
2022
A phase 2, double-blind, randomized controlled trial of PROSTVAC in prostate cancer patients on active surveillance
A phase , double-blind, randomized controlled trial of PROSTVAC in prostate cancer patients on active surveillanceJK Parsons, PA Pinto, CP Pavlovich, E Uchio, MN Nguyen, HL Kim, ...European Urology Focus 9 (3), 447-454, 030
2
2023
Adaptive immunity in genitourinary cancers
M Koti, T Bivalacqua, PC Black, T Cathomen, MD Galsky, JL Gulley, ...European Urology Oncology, 030
2
2023
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors
F Barlesi, N Isambert, E Felip, BC Cho, DH Lee, J Peguero, G Jerusalem, ...The Oncologist 8 (3), 58-67, 030
2
2023
A single-arm phase ii study combining NLG207, a nanoparticle camptothecin, with enzalutamide in advanced metastatic castration-resistant prostate cancer post-enzalutamide
A single-arm phase ii study combining NLG07, a nanoparticle camptothecin, with enzalutamide in advanced metastatic castration-resistant prostate cancer post-enzalutamideKT Schmidt, F Karzai, M Bilusic, LM Cordes, CH Chau, CJ Peer, ...The Oncologist 7 (9), 718-e694, 0
2
2022
A Phase I Single-Arm Study of Biweekly NHS-IL12 in Patients With Metastatic Solid Tumors
A Phase I Single-Arm Study of Biweekly NHS-IL2 in Patients With Metastatic Solid TumorsME Gatti-Mays, NP Tschernia, J Strauss, RA Madan, FH Karzai, M Bilusic, ...The Oncologist 28 (4), 364-e27, 2023202
1
2023
Phase 1 trial of CV301 in combination with anti‐PD‐1 therapy in nonsquamous non‐small cell lung cancer
Phase trial of CV30 in combination with anti‐PD‐ therapy in nonsquamous non‐small cell lung cancerA Rajan, JE Gray, S Devarakonda, R Birhiray, B Korchin, E Menius, ...International Journal of Cancer 52 (3), 447-457, 2023202
1
2023
Multi-spectral immunofluorescence evaluation of the myeloid, T cell, and natural killer cell tumor immune microenvironment in chordoma may guide immunotherapeutic strategies
DC Lopez, YL Robbins, JT Kowalczyk, W Lassoued, JL Gulley, ...Frontiers in Oncology 2, 02058, 2022202
1
2022
STAR0602, a novel TCR agonist antibody, demonstrates potent antitumor activity in refractory solid tumor models through the expansion of a novel, polyclonal effector memory T …
JL Gulley, A Bayliffe, R Donahue, YT Tsai, K Liu, M Katraggada, J Hsu, ...European Journal of Cancer 74, S5, 2022202
1
2022

Referred From: https://scholar.google.com/citations?user=9812F_0AAAAJ&hl=en

Cited by
Citations 26575
h-index 84
i10-index 324
Recommended Journals
Open Access Journals